US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
FR2646438B1
(fr)
*
|
1989-03-20 |
2007-11-02 |
Pasteur Institut |
Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
|
ES2090297T5
(es)
*
|
1989-11-06 |
2005-03-01 |
Cell Genesys, Inc. |
Produccion de proteinas que utilizan recombinacion homologa.
|
US5272071A
(en)
*
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
EP0779362B2
(en)
*
|
1989-12-22 |
2012-06-13 |
Laboratoires Serono SA |
DNA constructs for endogenous gene activation and expression modification
|
GB9028062D0
(en)
*
|
1990-12-24 |
1991-02-13 |
Agricultural & Food Res |
Production of transgenic animals
|
SG93780A1
(en)
*
|
1991-05-06 |
2003-01-21 |
Cell Genesys Inc |
Gene manipulation and expression using genomic elements
|
ES2214474T3
(es)
*
|
1991-05-31 |
2004-09-16 |
Genentech, Inc. |
Aumento de la expresion mediante orientacion genica en secuencias endogenas de tipo retrovirus.
|
AU2515992A
(en)
*
|
1991-08-20 |
1993-03-16 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
PT101031B
(pt)
*
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US5641670A
(en)
*
|
1991-11-05 |
1997-06-24 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US20020108136A1
(en)
*
|
1997-03-21 |
2002-08-08 |
Sri |
Transgenic animals produced by homologous sequence targeting
|
WO1993024642A1
(en)
*
|
1992-06-04 |
1993-12-09 |
Exemplar Corporation |
Insertion of heterologous dna outside of known chromosomal genes
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US5733753A
(en)
*
|
1992-12-22 |
1998-03-31 |
Novo Nordisk A/S |
Amplification of genomic DNA by site specific integration of a selectable marker construct
|
EP1403376A3
(en)
|
1993-04-21 |
2007-08-29 |
The University Court Of The University Of Edinburgh |
Expression of heterologous genes according to a targeted expression profile
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US5798448A
(en)
|
1994-10-27 |
1998-08-25 |
Genentech, Inc. |
AL-1 neurotrophic factor antibodies
|
US6610296B2
(en)
|
1995-10-26 |
2003-08-26 |
Genentech, Inc. |
Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
|
EP1619250B1
(en)
|
1996-01-08 |
2009-11-25 |
Genentech, Inc. |
OB receptor variant and ligands
|
US7148004B1
(en)
|
1997-01-16 |
2006-12-12 |
The Rockefeller University |
Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
|
US7063958B1
(en)
|
1996-01-16 |
2006-06-20 |
The Rockefeller University |
Nucleic acids db, the receptor for leptin
|
US7084252B1
(en)
|
1996-01-16 |
2006-08-01 |
The Rockefeller University |
DB, the receptor for leptin
|
US7619079B2
(en)
|
1996-02-14 |
2009-11-17 |
The Rockefeller University |
Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
|
US5792210A
(en)
*
|
1996-06-10 |
1998-08-11 |
Environmental Behavior Modification Inc. |
Electrical tongue stimulator and method for addiction treatment
|
CA2263883C
(en)
|
1996-08-29 |
2003-07-08 |
The Regents Of The University Of California |
Kuz, a novel family of metalloproteases
|
US6566089B1
(en)
|
1996-09-04 |
2003-05-20 |
Tularik Inc. |
Cell-based drug screens for regulators of gene expression
|
US5958727A
(en)
*
|
1996-09-13 |
1999-09-28 |
Novo Nordisk Biotech, Inc |
Methods for modifying the production of a polypeptide
|
JPH10117771A
(ja)
*
|
1996-10-23 |
1998-05-12 |
Natl Food Res Inst |
冷凍生地耐性実用パン酵母
|
US5925544A
(en)
*
|
1996-11-18 |
1999-07-20 |
Novo Nordisk A/S |
Method of homologous recombination followed by in vivo selection of DNA amplification
|
US6326204B1
(en)
*
|
1997-01-17 |
2001-12-04 |
Maxygen, Inc. |
Evolution of whole cells and organisms by recursive sequence recombination
|
US7148054B2
(en)
*
|
1997-01-17 |
2006-12-12 |
Maxygen, Inc. |
Evolution of whole cells and organisms by recursive sequence recombination
|
IL130635A0
(en)
|
1997-01-17 |
2000-06-01 |
Maxygen Inc |
Evolution of whole cells and organisms by recursive sequence recombination
|
US6025157A
(en)
*
|
1997-02-18 |
2000-02-15 |
Genentech, Inc. |
Neurturin receptor
|
US6777196B2
(en)
|
1997-02-18 |
2004-08-17 |
Genentech, Inc. |
Neurturin receptor
|
US6372453B1
(en)
|
1997-02-18 |
2002-04-16 |
Genetech, Inc. |
Neurturin receptor
|
WO1998041645A1
(en)
|
1997-03-14 |
1998-09-24 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
US5948653A
(en)
*
|
1997-03-21 |
1999-09-07 |
Pati; Sushma |
Sequence alterations using homologous recombination
|
US6172211B1
(en)
|
1997-07-11 |
2001-01-09 |
Boehringer Ingelheim International Gmbh |
Nucleic acid encoding tag7 polypeptide
|
US6391633B1
(en)
|
1997-07-23 |
2002-05-21 |
Roche Diagnostics Gmbh |
Production of erythropoietin by endogenous gene activation
|
ES2273434T3
(es)
*
|
1997-07-23 |
2007-05-01 |
Roche Diagnostics Gmbh |
Obtencion de la eritropoyetina mediante activacion genica endogena.
|
PT1000154E
(pt)
|
1997-07-23 |
2007-03-30 |
Roche Diagnostics Gmbh |
Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
|
DK1000154T3
(da)
*
|
1997-07-23 |
2007-06-18 |
Roche Diagnostics Gmbh |
Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
|
US6548296B1
(en)
|
1997-07-23 |
2003-04-15 |
Roche Diagnostics Gmbh |
Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
|
US6897066B1
(en)
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6740503B1
(en)
|
1997-09-26 |
2004-05-25 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
WO1999015650A1
(en)
*
|
1997-09-26 |
1999-04-01 |
Athersys, Inc. |
Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
|
ZA989497B
(en)
†
|
1997-10-20 |
2000-04-19 |
Roche Diagnostics Gmbh |
Positive-negative selection in homologous recombination.
|
CN1280619A
(zh)
|
1997-11-28 |
2001-01-17 |
根瑟特公司 |
沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
|
AU757930B2
(en)
*
|
1997-12-01 |
2003-03-13 |
Roche Diagnostics Gmbh |
Optimization of cells for endogenous gene activation
|
JPH11243944A
(ja)
*
|
1998-03-04 |
1999-09-14 |
Natl Food Res Inst |
製パン用乾燥耐性実用パン酵母
|
US6541623B1
(en)
|
1998-04-03 |
2003-04-01 |
Hyseq, Inc. |
Interleukin—1 receptor antagonist and uses thereof
|
US6426191B1
(en)
|
1998-04-03 |
2002-07-30 |
Hyseq, Inc. |
Assays involving an IL-1 receptor antagonist
|
US6294655B1
(en)
|
1998-04-03 |
2001-09-25 |
Hyseq, Inc. |
Anti-interleukin-1 receptor antagonist antibodies and uses thereof
|
US6337072B1
(en)
|
1998-04-03 |
2002-01-08 |
Hyseq, Inc. |
Interleukin-1 receptor antagonist and recombinant production thereof
|
KR100795626B1
(ko)
|
1998-07-21 |
2008-01-17 |
코브라 바이오매뉴팩쳐링 피엘씨. |
도처에 있는 염색질 개방 요소(유씨오이)를 포함하는폴리뉴클레오티드
|
EP1123401A1
(en)
*
|
1998-10-22 |
2001-08-16 |
The General Hospital Corporation |
BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
TW570977B
(en)
*
|
1998-12-07 |
2004-01-11 |
Li-Wei Hsu |
An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
ATE421976T1
(de)
|
1999-05-18 |
2009-02-15 |
Dyax Corp |
Fab fragmentbibliotheken und verfahren für deren verwendung
|
US6495360B1
(en)
*
|
1999-05-28 |
2002-12-17 |
Photogen, Inc. |
Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
|
US20050129669A1
(en)
*
|
1999-06-21 |
2005-06-16 |
Transkaryotic Therapies, Inc., A Massachusetts Corporation |
DNA construct for effecting homologous recombination and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
ATE412670T1
(de)
|
1999-09-29 |
2008-11-15 |
Gen Hospital Corp |
Parathyroid hormon (pth) polypeptidderivate
|
WO2001023521A2
(en)
*
|
1999-09-29 |
2001-04-05 |
The General Hospital Corporation |
Polypeptide derivatives of parathyroid hormone (pth)
|
WO2001042442A2
(en)
|
1999-12-10 |
2001-06-14 |
Cytos Biotechnology Ag |
Activation of endogenous genes by genomic introduction of a replicon
|
WO2001051646A2
(en)
*
|
2000-01-13 |
2001-07-19 |
Novozymes Biotech, Inc. |
Methods for producing a polypeptide using a crippled translational initiator sequence
|
AU2001243345A1
(en)
|
2000-02-29 |
2001-09-12 |
Millennium Pharmaceuticals, Inc. |
1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
|
EP1714661A3
(en)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
US6686188B2
(en)
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
GB0018876D0
(en)
|
2000-08-01 |
2000-09-20 |
Applied Research Systems |
Method of producing polypeptides
|
CN1468250A
(zh)
*
|
2000-08-03 |
2004-01-14 |
��ķһ����˹��̹ |
在转基因动物中产生人源化抗体
|
US6803211B2
(en)
|
2000-08-25 |
2004-10-12 |
Pfizer Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
US7311905B2
(en)
|
2002-02-13 |
2007-12-25 |
Anthrogenesis Corporation |
Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
|
DK1349918T3
(da)
|
2000-12-06 |
2014-11-10 |
Anthrogenesis Corp |
Fremgangsmåde til indsamling af stamceller fra moderkagen
|
WO2002049673A2
(en)
|
2000-12-20 |
2002-06-27 |
F. Hoffmann-La Roche Ag |
Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
|
CN100528235C
(zh)
*
|
2000-12-20 |
2009-08-19 |
霍夫曼-拉罗奇有限公司 |
红细胞生成素共轭物
|
PA8536201A1
(es)
|
2000-12-29 |
2002-08-29 |
Kenneth S Warren Inst Inc |
Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
|
EP2336299A1
(en)
|
2001-02-14 |
2011-06-22 |
Anthrogenesis Corporation |
Post-partum mammalian placenta, its use and placental stem cells therefrom
|
KR100973615B1
(ko)
|
2001-02-14 |
2010-08-02 |
안트로제네시스 코포레이션 |
산후 포유류의 태반, 이의 용도 및 태반 줄기세포
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
EP1423521B1
(en)
|
2001-06-06 |
2008-08-13 |
Bioriginal Food & Science Corp. |
Flax (linum usitatissimum l.) seed-specific sequences
|
EP1925671A1
(en)
|
2001-06-06 |
2008-05-28 |
Bioriginal Food & Science Corp. |
Flax (Linum usitatissimum L.) seed-specific promoters
|
JP4837888B2
(ja)
*
|
2001-07-23 |
2011-12-14 |
ザ ジェネラル ホスピタル コーポレイション |
コンホメーションが拘束された副甲状腺ホルモン(pth)類似体
|
ES2429132T3
(es)
|
2001-08-31 |
2013-11-13 |
The Rockefeller University |
Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP1455815A4
(en)
|
2001-12-19 |
2006-11-02 |
Millennium Pharm Inc |
MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
|
EP1468099A2
(en)
*
|
2002-01-17 |
2004-10-20 |
Lonza Biologics plc |
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
|
EP2301343A1
(en)
|
2002-02-13 |
2011-03-30 |
Anthrogenesis Corporation |
Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
|
US7682803B2
(en)
|
2005-10-13 |
2010-03-23 |
Anthrogenesis Corporation |
Immunomodulation using placental stem cells
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
WO2003094841A2
(en)
*
|
2002-05-06 |
2003-11-20 |
Functional Genetics, Inc. |
Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes
|
WO2003100007A2
(en)
|
2002-05-24 |
2003-12-04 |
Schering-Plough Ltd. |
Eta-1 gene and methods for use
|
AU2003265525A1
(en)
*
|
2002-08-15 |
2004-03-19 |
Functional Genetics, Inc. |
Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes
|
WO2004020582A2
(en)
*
|
2002-08-15 |
2004-03-11 |
Functional Genetics, Inc. |
Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
AU2003293013A1
(en)
|
2002-11-21 |
2004-06-18 |
University Of Massachusets |
Diagnosing and treating hematopoietic cancers
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
CN1717177A
(zh)
|
2002-11-26 |
2006-01-04 |
人类起源公司 |
细胞治疗剂、细胞治疗单元及其用于治疗的方法
|
JP2006517101A
(ja)
*
|
2003-01-13 |
2006-07-20 |
エス. ラオ、マヘンドラ |
治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現
|
US20050048041A1
(en)
*
|
2003-01-13 |
2005-03-03 |
Rao Mahendra S. |
Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
|
EP1594433B8
(en)
|
2003-01-14 |
2016-12-21 |
Dana-Farber Cancer Institute, Inc. |
Cancer therapy sensitizer
|
US8021833B2
(en)
|
2003-02-12 |
2011-09-20 |
Functional Genetics, Inc. |
Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
|
AU2003220380A1
(en)
*
|
2003-03-19 |
2004-11-19 |
Bristol-Myers Squibb Company |
CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
|
JP4871128B2
(ja)
|
2003-07-17 |
2012-02-08 |
ザ ジェネラル ホスピタル コーポレイション |
高次構造的に制約された副甲状腺ホルモン(pth)アナログ
|
US7287952B2
(en)
*
|
2003-07-23 |
2007-10-30 |
Lockheed Martin Corporation |
Feeder load automation system and method of use
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7645733B2
(en)
|
2003-09-29 |
2010-01-12 |
The Kenneth S. Warren Institute, Inc. |
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
|
ATE552276T1
(de)
|
2003-11-01 |
2012-04-15 |
Merck Patent Gmbh |
Modifizierter anti-cd52-antikörper
|
CN1901934B
(zh)
*
|
2003-12-19 |
2013-09-11 |
弗·哈夫曼-拉罗切有限公司 |
促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途
|
ATE409741T1
(de)
*
|
2004-01-19 |
2008-10-15 |
Nsgene As |
Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen
|
EP1784510A4
(en)
|
2004-08-02 |
2010-08-04 |
Janssen Pharmaceutica Nv |
IRAK1C SPLICE VARIANT AND USE THEREOF
|
US7893197B2
(en)
|
2004-08-25 |
2011-02-22 |
Janssen Pharmaceutica N.V. |
Relaxin-3 chimeric polypeptides and their preparation and use
|
US7893034B2
(en)
|
2004-09-02 |
2011-02-22 |
Yale University |
Regulation of oncogenes by microRNAs
|
US20060130157A1
(en)
|
2004-10-22 |
2006-06-15 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2595676A1
(en)
*
|
2005-01-25 |
2006-08-03 |
Apollo Life Sciences Limited |
Molecules and chimeric molecules thereof
|
US8088978B2
(en)
|
2005-02-09 |
2012-01-03 |
Bioriginal Food & Science Corp. |
Omega-3 fatty acid desaturase family members and uses thereof
|
DK1874282T3
(da)
|
2005-04-06 |
2010-10-25 |
Adamas Pharmaceuticals Inc |
Fremgangsmåder og præparater til behandling af CNS lidelser
|
US8354384B2
(en)
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
US7767420B2
(en)
|
2005-11-03 |
2010-08-03 |
Momenta Pharmaceuticals, Inc. |
Heparan sulfate glycosaminoglycan lyase and uses thereof
|
US8014957B2
(en)
|
2005-12-15 |
2011-09-06 |
Fred Hutchinson Cancer Research Center |
Genes associated with progression and response in chronic myeloid leukemia and uses thereof
|
ZA200804718B
(en)
|
2005-12-29 |
2010-04-28 |
Anthrogenesis Corp |
Co-culture of placental stem cells and stem cells from a second source
|
ES2711278T3
(es)
|
2005-12-29 |
2019-04-30 |
Celularity Inc |
Poblaciones de células madre placentarias
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
SI2004683T1
(sl)
|
2006-03-24 |
2016-09-30 |
Biogen Hemophilia Inc. |
Pc5 kot encim za obdelavo propeptida faktorja ix
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
AU2007257162A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
ES2529234T3
(es)
*
|
2006-08-04 |
2015-02-18 |
Prolong Pharmaceuticals, LLC |
Eritropoyetina modificada
|
JP2009545320A
(ja)
*
|
2006-08-04 |
2009-12-24 |
ザ ジェネラル ホスピタル コーポレイション |
副甲状腺ホルモン(pth)のポリペプチド誘導体
|
PL2064325T3
(pl)
|
2006-09-01 |
2012-05-31 |
Therapeutic Human Polyclonals Inc |
Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek
|
EP2420567A3
(en)
|
2006-10-23 |
2015-09-30 |
Anthrogenesis Corporation |
Methods and compositions for treatment of bone defects with placental cell populations
|
CA2667196A1
(en)
|
2006-10-30 |
2008-11-06 |
Functional Genetics, Inc. |
Random homozygous gene perturbation to enhance antibody production
|
NZ578819A
(en)
|
2007-02-12 |
2012-02-24 |
Anthrogenesis Corp |
Treatment of inflammatory diseases using placental stem cells
|
EP2079839A4
(en)
|
2007-03-05 |
2009-11-18 |
Cancer Care Ontario |
ASSESSMENT OF COLORECTAL CARCINOMA RISK
|
EA200971050A1
(ru)
|
2007-05-11 |
2010-06-30 |
Томас Джефферсон Юниверсити |
Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
|
CN101687009A
(zh)
|
2007-05-11 |
2010-03-31 |
宾夕法尼亚大学理事会 |
治疗皮肤溃疡的方法
|
US8252897B2
(en)
|
2007-06-21 |
2012-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
CL2008002053A1
(es)
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
|
CL2008002054A1
(es)
|
2007-07-17 |
2009-05-29 |
Hoffmann La Roche |
Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
MX346714B
(es)
*
|
2007-08-01 |
2017-03-24 |
The General Hospital Corp * |
Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
|
US9200253B1
(en)
|
2007-08-06 |
2015-12-01 |
Anthrogenesis Corporation |
Method of producing erythrocytes
|
EP2567969A1
(en)
|
2007-09-24 |
2013-03-13 |
Cornell University |
Immunogenic proteins from genome-derived outer membrane of Leptospira and compositions and methods based thereon
|
EP3524253A1
(en)
|
2007-09-28 |
2019-08-14 |
Celularity, Inc. |
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
|
US8501449B2
(en)
|
2007-12-04 |
2013-08-06 |
Proteon Therapeutics, Inc. |
Recombinant elastase proteins and methods of manufacturing and use thereof
|
EP2570501A3
(en)
|
2008-01-02 |
2013-04-10 |
Suregene Llc |
Genetic markers of mental illness
|
EP2581453A3
(en)
|
2008-01-17 |
2013-07-10 |
Suregene Llc |
Genetic Markers of Mental Illness
|
CA2717169A1
(en)
*
|
2008-03-01 |
2009-09-17 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
|
EP3369827B1
(en)
|
2008-03-12 |
2020-12-23 |
The Rockefeller University |
Methods and compositions for translational profiling and molecular phenotyping
|
US20090280167A1
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
DK2330889T3
(en)
|
2008-08-20 |
2017-01-30 |
Anthrogenesis Corp |
Improved cell composition and process for making the same
|
US8962247B2
(en)
|
2008-09-16 |
2015-02-24 |
Sequenom, Inc. |
Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
|
US8476013B2
(en)
|
2008-09-16 |
2013-07-02 |
Sequenom, Inc. |
Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
|
EP2344672B8
(en)
|
2008-09-25 |
2014-12-24 |
SureGene LLC |
Genetic markers for optimizing treatment for schizophrenia
|
KR102097887B1
(ko)
|
2008-09-26 |
2020-04-06 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
WO2010037224A1
(en)
|
2008-10-03 |
2010-04-08 |
St. Michael's Hospital |
Method for preventing and treating cardiovascular diseases with brca1
|
US20100120063A1
(en)
*
|
2008-10-10 |
2010-05-13 |
Discoverx Corporation |
GPCR Arrestin Assays
|
ES2548377T3
(es)
|
2008-10-27 |
2015-10-16 |
Revivicor, Inc. |
Ungulados inmunodeprimidos
|
EA201170647A1
(ru)
|
2008-11-04 |
2011-12-30 |
Янссен Фармацевтика Нв |
Пептиды-агонисты crhr2 и их использование
|
KR20110086176A
(ko)
|
2008-11-19 |
2011-07-27 |
안트로제네시스 코포레이션 |
양막 유래 부착성 세포
|
WO2010084488A1
(en)
|
2009-01-20 |
2010-07-29 |
Ramot At Tel-Aviv University Ltd. |
Mir-21 promoter driven targeted cancer therapy
|
US8530629B2
(en)
|
2009-01-30 |
2013-09-10 |
Ab Biosciences, Inc. |
Lowered affinity antibodies and uses therefor
|
US8211655B2
(en)
*
|
2009-02-12 |
2012-07-03 |
Discoverx Corporation |
Wild-type receptor assays
|
KR20120103606A
(ko)
|
2009-11-04 |
2012-09-19 |
얀센 파마슈티카 엔.브이. |
스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
|
US8968740B2
(en)
|
2009-11-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
EP2516680B1
(en)
|
2009-12-22 |
2016-04-06 |
Sequenom, Inc. |
Processes and kits for identifying aneuploidy
|
WO2011094181A1
(en)
|
2010-01-26 |
2011-08-04 |
Anthrogenesis Corporation |
Treatment of bone-related cancers using placental stem cells
|
JP6101489B2
(ja)
|
2010-01-28 |
2017-03-22 |
アブ バイオサイエンシズ インコーポレイテッド |
親和性が低下した抗体およびそれを作製する方法
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
HUE029144T2
(hu)
|
2010-04-07 |
2017-02-28 |
Anthrogenesis Corp |
Angiogenezis méhlepény õssejtek használatával
|
US9492508B2
(en)
|
2010-05-13 |
2016-11-15 |
The General Hospital Corporation |
Parathyroid hormone analogs and uses thereof
|
CN103097520B
(zh)
|
2010-07-13 |
2017-12-05 |
人类起源公司 |
产生自然杀伤细胞的方法
|
DK2601609T3
(en)
|
2010-08-02 |
2017-06-06 |
Population Bio Inc |
COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
|
WO2012035037A1
(en)
|
2010-09-14 |
2012-03-22 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
CN103328038A
(zh)
|
2010-12-01 |
2013-09-25 |
史拜诺莫度雷森公司 |
向神经解剖结构直接递送药剂
|
EP2471543A1
(en)
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
AU2011352036A1
(en)
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
CN113559126A
(zh)
|
2011-06-01 |
2021-10-29 |
人类起源公司 |
利用胎盘干细胞治疗疼痛
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CA2844197A1
(en)
|
2011-08-03 |
2013-02-07 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System |
Treatment of fibrosis using microrna-19b
|
EP2766483B1
(en)
|
2011-10-10 |
2022-03-23 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
DK2773779T3
(da)
|
2011-11-04 |
2020-11-23 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
|
US10407724B2
(en)
|
2012-02-09 |
2019-09-10 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
ES2690786T3
(es)
|
2012-02-15 |
2018-11-22 |
Novo Nordisk A/S |
Anticuerpos que se unen a la proteína 1 de reconocimiento de peptidoglicano
|
PL2814844T3
(pl)
|
2012-02-15 |
2017-12-29 |
Novo Nordisk A/S |
Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP4155401A1
(en)
|
2012-03-02 |
2023-03-29 |
Sequenom, Inc. |
Methods and processes for non-invasive assessment of genetic variations
|
US9494597B2
(en)
|
2012-04-02 |
2016-11-15 |
Ab Biosciences, Inc. |
Human control antibodies and uses therefor
|
WO2013158309A2
(en)
*
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
US9920361B2
(en)
|
2012-05-21 |
2018-03-20 |
Sequenom, Inc. |
Methods and compositions for analyzing nucleic acid
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
WO2014011928A1
(en)
|
2012-07-13 |
2014-01-16 |
Sequenom, Inc. |
Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
WO2014052855A1
(en)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
CN103864913A
(zh)
|
2012-12-18 |
2014-06-18 |
联亚生技开发股份有限公司 |
重组蛋白
|
AU2014215458A1
(en)
|
2013-02-05 |
2015-08-13 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
WO2014168711A1
(en)
|
2013-03-13 |
2014-10-16 |
Sequenom, Inc. |
Primers for dna methylation analysis
|
WO2014138921A1
(en)
|
2013-03-15 |
2014-09-18 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
EP2968450A4
(en)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
US10294295B2
(en)
|
2013-11-27 |
2019-05-21 |
Inis Biotech Llc |
Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
|
CN106661107B
(zh)
|
2013-12-24 |
2021-12-24 |
杨森制药公司 |
抗vista抗体及片段
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3736344A1
(en)
|
2014-03-13 |
2020-11-11 |
Sequenom, Inc. |
Methods and processes for non-invasive assessment of genetic variations
|
JP2017509328A
(ja)
|
2014-03-21 |
2017-04-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ヌクレアーゼを使用しないゲノム編集
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
US10724096B2
(en)
|
2014-09-05 |
2020-07-28 |
Population Bio, Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
JP6841753B2
(ja)
|
2014-09-15 |
2021-03-10 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
WO2016118832A1
(en)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Cancer immunotherapy
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
EP3413910A1
(en)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5) antibodies
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
CA3027143A1
(en)
|
2016-07-15 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
US10766798B2
(en)
*
|
2017-02-02 |
2020-09-08 |
Massachusetts Institute Of Technology |
Engineered yeast as a method for bioremediation
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
SI3731872T1
(sl)
|
2017-12-29 |
2022-04-29 |
F. Hoffmann-La Roche Ag |
Postopek za zagotavljanje sestavka PEGiliranih beljakovin
|
SG11202005990RA
(en)
|
2017-12-29 |
2020-07-29 |
Hoffmann La Roche |
Process for providing pegylated protein composition
|
ES2909454T3
(es)
|
2017-12-29 |
2022-05-06 |
Hoffmann La Roche |
Procedimiento para proporcionar una composición de proteína PEGilada
|
EP3625368B8
(en)
|
2018-08-08 |
2022-12-14 |
PML Screening, LLC |
Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
|
US20230201334A1
(en)
|
2019-07-24 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
WO2023144665A1
(en)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|